0.00Open33.20Pre Close0 Volume3 Open Interest220.00Strike Price0.00Turnover45.24%IV0.46%PremiumDec 20, 2024Expiry Date32.04Intrinsic Value100Multiplier25DDays to Expiry1.17Extrinsic Value100Contract SizeAmericanOptions Type0.8923Delta0.0062Gamma7.28Leverage Ratio-0.1326Theta0.1315Rho6.50Eff Leverage0.1228Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet